Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 20 March 2026
Revised 22 April 2026
Accepted 08 May 2026

Natural Resources for Human Health 2026, Vol. 6 (3): 424–431

KEYWORDS:
Terminalia arjuna; Seasonal variation; Total phenolic content; Antioxidant capacity; Flavonoids; DPPH assay; FRAP assay; Pharmacognosy; Phytochemicals; Herbal standardization.

Seasonal Variation in Phenolic Content and Antioxidant Capacity of Terminalia arjuna Bark

Sushma Verma[1], Sumeet Kaur[2], V. Shanmugapriya[3], S. Aishwarya[4], Jagdish Kumar Arun[5], Abduvokhid Boltayev[6], Ramnath V[7], Menmozhi T[8]

[1]Professor, Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, India, sushmaverma.pharmacy@niet.co.in, 0000-0002-7816-4625
[2]Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India. sumeet.kaur.orp@chitkara.edu.in https://orcid.org/0009-0004-7059-7583
[3]Professor Department of Biochemistry Vinayaka Missions Medical College, Karaikal Vinayaka Mission's Research Foundation (DU), Tamil Nadu, India. priyasri@live.com 0000-0002-6331-5523
[4]Assistant Professor, School of pharmacy, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India, aishwarya.pharmacy@sathyabama.ac.in, 0009-0009-0174-454X
[5]Professor, Department of Pharmacy, Vivekananda Global University, Jaipur, India, jagdish.arun@vgu.ac.in, 0009-0000-2710-1408
[6]Adjunct professor, Faculty of Preschool and Primary Education, Doctor of Philosophy in Pedagogical Sciences (PhD), Jizzakh State Pedagogical University, boltayevabduvoxid79@gmail.com, 0009-0003-6793-6540
[7]Meenakshi College of Allied Health Sciences, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, ramnathv@maher.ac.in
[8]Meenakshi College of Physiotherapy, Meenakshi Academy of Higher Education and Research, menmozhi@maher.ac.in

ABSTRACT: Background: Determining a good harvest time can enhance consistency and control of pharmacognostics. Objective: To compare between-season comparison with prospective seasonal analytical study to compare the analyses of four seasons of collected samples of the barks. Methods: It had 48 experimental units or participants of mature Terminalia arjuna trees sampled in three geographically similar locations. The intervention was followed or experimented on 12 months. The major product at the end was total phenolic content, and further evaluation of total flavonoid content, DPPH IC50, FRAP value, moisture-corrected extractive yield. Standardized laboratory, clinical, or food-analysis procedures were applied, and between-condition effects were evaluated with two-sided tests at α=0.05. Results: Post-monsoon bark had the highest total phenolic content (172 ± 15 mg GAE/g), exceeding monsoon samples by 57.8% ($p<0.001$). Post-monsoon samples also showed the strongest ferric-reducing capacity (2.63 ± 0.24 mmol Fe2+/g) and the lowest DPPH IC50 (27 ± 3 μg/mL); phenolic content correlated strongly with FRAP values (r=0.91).

The direction and magnitude of the dummy results were internally consistent between primary and secondary endpoints and tolerability or assay-quality thresholds was acceptable. Conclusion: The example dataset indicates that the bark samples taken in four

seasons might yield a significant change in total phenolic content by environmentally responsive distribution of phenolic metabolites and seasonal alterations in oxidative defense chemistry. The findings are only meant to serve as an example of a full manuscript development but would have to be substituted with ethically generated, independently verified observations to be submitted scientifically. Keywords: Terminalia arjuna; seasonal variation; phenolics; antioxidant capacity; pharmacognosy.

1. INTRODUCTION

The question that Seasonal Variation in Phenolic Content and Antioxidant Capacity of Terminalia arjuna Bark is concerned with is significant at the border of experimental pharmacology, nutritional science and translational health research. Published work that is directly related has provided a scientific foundation on which to assess the samples of bark that have been gathered in four seasons as compared to the total phenolic content [1]. However, the differences in the preparation, exposure, choice of comparators, and outcome definition remain to impede the comparison of studies with confidence.

The second line of evidence helps to prove that the current hypothesis is biologically plausible. Functional or biochemical activity that is consistent with the direction of benefit has been previously documented in Terminalia arjuna and interventions closely related to it [2]. These observations warrant formal tests but do not preclude standardized materials and predetermined criteria of analysis.

The broader natural-product and functional-food literature demonstrates that reproducibility requires chemical characterization, processing conditions, dose, biological matrix, and stability of active constituents [3]. In the current study, the collection of bark samples in four seasons could thus be considered a research-level intervention instead of an unspecified customary or commercial preparation.

The suggested mechanism is the environmental responsive distribution of phenolic compounds and seasonal adaptations of oxidative defense chemistry. Evidence published suggests that related biological reactions tend to be associated with interacting redox, inflammatory, metabolic, microbial, enzymatic, or differentiation pathways and not a single isolated target [4]. Simultaneously measurement of a primary functional endpoint and mechanistic markers can thus give a more consistent interpretation.

The methods also need to be appropriate to the study model in outcome assessment. Standardized sample processing, proved analysis methods, proper controls and pre-specified interpretation limits are considered in established laboratory/clinical methodology [5]. These guidelines were used to select total phenolic content as the main outcome and the secondary endpoints.

When the total phenolic content is altered, concordant alterations in total flavonoid content and DPPH IC50 are the most persuasive changes. Similar studies have shown the importance of the integration of functional, biochemical, and structural results in assessing complex botanical, microbial, or food-based interventions [6].

Quality and safety are also crucial. Natural origin does not assure stable composition and absence of adverse effects, contaminants, interactions and degradation, and published pharmacovigilance and quality-control data suggest combining these considerations early in the product development [7].

Lastly, there should be clear study design in order to minimize bias. Randomization, blinding where possible, replication, full reporting of exclusions, and reporting of effect estimates (as opposed to using p-values) are guided by prior methodological studies applicable to the current experimental model [8].

Although the evidence is available, not many studies have presented a well-defined sample of bark samples taken in four seasons, a suitable comparator, a pre-specified primary endpoint, and supporting mechanistic or feasibility results on mature trees of Terminalia arjuna sampled at three geographically similar locations. This study was thus conducted with the objective of establishing the impact of the bark samples picked during four seasons on total phenolic content as opposed to between-season comparison. Secondary was to assess the total flavonoid content, DPPH IC50, FRAP value, and quality or safety indicators.

2. MATERIALS AND METHODS

2.1. Study design and setting

The following manuscript is a prespecified prospective seasonal analytical study that was carried out on mature Terminalia aruna trees sampled in three geographically compatible sites. The designed sample included 48 experimental units or participants and was designed to be able to compare the samples of the bark taken in four seasons and compare them between seasons. The time of observation was 12 months. Every figure in this paper is dummy/example data that is generated to draft the paper, demonstrate statistically, construct tables, and prepare graphs; it is not observations of an actual completed study. The design is however based on realistic laboratory or clinical procedures such that the draft could later be modified to an approved protocol and substituted with real measurements.

2.2. Materials and sampling

The sampling plan was documented to obtain materials in order to reflect batch or seasonal variation. Identity of sampled mature Terminalia arjuna trees in three geographically matched sites would be verified through botanical, physical or supplier records and a voucher specimen or reference would be stored. A coding of the samples was done, followed by the correction of moisture when necessary, and the replicate analysis. Each run had instruments calibrated with traceable standards and analytical blanks, controls and quality-control samples.

2.3. Preparation and experimental conditions

Bark samples were collected during four seasons, and with the help of standardized processing parameters, the intervention material was created. The comparison was between-season comparison. The critical variables including particle size, extraction ratio, mixing time, fermentation temperature, cooking conditions or packaging were kept constant except the formulation factor specified. Independent preparation of each batch was also done to allow the estimation of the between-batch variability in lieu of repeated measurements within a single production run.

2.4. Outcome assessment

The main result was the total phenolic content in terms of mg GAE/g. The secondary outcomes were total flavonoid content, DPPH IC50, FRAP value, moisture-corrected extractive yield. Depending on the design, baseline and follow-up or across conditions of concentration and time were planned to be measured. Assays were done based on validated kit instructions or analytical standard procedures, and when the coefficient of variation was greater than 10, duplicate measurements were done. After a standardized period of rest, clinical measurements were taken and the results of food-products were evaluated under controlled server conditions.

2.5. Quality assurance and bias control

Sample labeling, timing limits, data entry and protocol deviation dealing were specified in a written laboratory or trial manual. Where the intervention format allowed, the outcome assessors were blinded. Conceptual recheck against source data was done on ten percent of records and only analytical run where calibration and quality-control samples were within predetermined limits was accepted. The display of primary complete cases did not address the cases that were missing; rather, sensitivity analysis employed an intention-to-treat framework or model-based estimation when appropriate.

2.6. Sample-size rationale

The sample of 48 units was planned to give realistic precision of a manuscript to develop. In the case of a real study, this calculation ought to be substituted by one that employs a pilot-derived standard deviation and the minimal clinically/biologically significant difference in total phenolic content. The final calculation should specify two-sided $\alpha=0.05$, desired power of at least 80%, allocation ratio, anticipated attrition or unusable assays, and any adjustment for repeated measures, clustering, or multiple primary comparisons.

2.7. Statistical analysis

When data were normally distributed, continuous data were summarized using mean + standard deviation and when skewed, they were summarized using median plus interquartile range. Categorical data were presented in number and percentage.

Independent t tests, Mann-Whitney tests, chi-square tests, or Fisher exact tests were used as appropriate tests between-group baseline comparisons. Dependent variables were measured using analysis of covariance, repeated-measures analysis, mixed-effects models, one-way analysis of variance with multiplicity-adjusted post hoc tests or nonparametric analogs depending on design. The estimates of the effects were followed by 95% confidence. Correlations were done using Pearlson or Spearman coefficients. All the tests are two-sided and $p<0.05$ was taken as statistically significant. Conceptual analyses were done using a current statistical package with an auditable syntax file.

3. RESULTS

The entire dummy/example dataset of the prospective seasonal analytical study was analysed. The balance of baseline characteristics, assay controls, or starting values was carried out between comparison conditions, and no predetermined quality-control run was discarded. The tables include mean ± standard deviation unless otherwise indicated. Since the data are pictorial, flow of participants, assays excluded, and p-values were produced to be statistically consistent, and not to reflect a real-life enrolled sample.

Post-monsoon bark had the highest total phenolic content (172 ± 15 mg GAE/g), exceeding monsoon samples by 57.8% ($p<0.001$).

Table 1. Pharmacognostic and extraction characteristics

Season	Moisture (%)	Extractive yield (%)	Ash (%)	Bark thickness (mm)
Winter	8.2 ± 0.8	15.8 ± 1.3	7.1 ± 0.5	6.8 ± 0.7
Spring	9.1 ± 0.9	17.6 ± 1.5	7.3 ± 0.5	7.1 ± 0.8
Monsoon	13.4 ± 1.2	14.2 ± 1.2	7.6 ± 0.6	7.5 ± 0.8
Post-monsoon	10.2 ± 1.0	19.1 ± 1.6	7.2 ± 0.5	7.2 ± 0.7

Values are dummy/example data presented as mean ± SD unless otherwise stated.

The trend of the main effect was corroborated by the alteration of total flavonoid content and DPPH IC50. Magnitude of response tended to be higher with exposure to intervention or higher at follow-up in the intervention arm, whereas the comparator had smaller changes. In situations where repeated measurements were possible, the effect of group by-time or condition was significant even after corrections were made by considering the baseline values and pre-planned multiple comparisons.

Table 2. Seasonal phytochemical content

Season	Total phenolics (mg GAE/g)	Flavonoids (mg QE/g)	Tannins (mg TAE/g)	Arjunolic acid (mg/g)
Winter	126 ± 11	42 ± 5	88 ± 9	8.1 ± 0.8
Spring	148 ± 13	51 ± 6	101 ± 10	9.4 ± 0.9
Monsoon	109 ± 10	36 ± 4	76 ± 8	7.2 ± 0.7
Post-monsoon	172 ± 15	61 ± 7	119 ± 11	10.8 ± 1.0

Values are dummy/example data presented as mean ± SD unless otherwise stated.

Post-monsoon samples also showed the strongest ferric-reducing capacity (2.63 ± 0.24 mmol Fe2+/g) and the lowest DPPH IC50 (27 ± 3 μg/mL); phenolic content correlated strongly with FRAP values ($r=0.91$).



Figure 1. Primary outcome based on dummy/example data.

Exploratory analyses revealed that the most relevant mechanistic marker was connected with the response in total phenolic content. The trend was in line with environmentally responsive distribution of phenolic metabolites and seasonal variation of oxidative defensive chemical. None of the extreme values changed the result direction in sensitivity analysis. In clinical and food studies, compliance and acceptability were defined within a set of predefined feasibility limits; in the laboratory studies, the variation in replicates and performance in control was contained within the intended range of analytical performance.

Table 3. Antioxidant capacity by season

Season	DPPH IC50 (µg/mL)	FRAP (mmol Fe2+/g)	ABTS inhibition (%)	Phenolic-FRAP correlation
Winter	42 ± 4	1.82 ± 0.18	68 ± 6	r=0.91
Spring	34 ± 3	2.16 ± 0.21	75 ± 6	r=0.91
Monsoon	51 ± 5	1.51 ± 0.16	61 ± 5	r=0.91
Post-monsoon	27 ± 3	2.63 ± 0.24	83 ± 7	r=0.91

Values are dummy/example data presented as mean ± SD unless otherwise stated.



Figure 2. Secondary or mechanistic outcome based on dummy/example data.

No unexpected safety signal was present in the example dataset. Mild events or assay artifacts were infrequent and balanced, and there were no serious adverse events, unplanned deaths, contamination failures, or invalid control runs unless explicitly shown in the tables. These observations are illustrative and must not be interpreted as evidence of real-world safety.

4. DISCUSSION

The present manuscript-development study indicates that bark samples collected in four seasons may improve total phenolic content compared with between-season comparison. The dummy findings were strengthened by concordant changes in total flavonoid content, DPPH IC50, and FRAP value. This internal consistency is important because agreement across functional and mechanistic endpoints is less likely to reflect isolated analytical variation.

The trend of the main outcome is generally in line with other published studies of standardized botanical or food-based interventions in analogous models [9]. In spite of protocols and populations, that literature also reports that the quality of preparations and dose can significantly affect the response magnitude.

Similar investigations also indicated alterations in inflammatory, oxidative, metabolic, microbial, structural, or functional results that justify multidimensional assessment in lieu of a surrogate marker [10]. The current trend thus fits a broader evidence base but at the same time, it is specific to the intervention and model under consideration in this case.

The mechanistic explanation can be bolstered by the fact that complex interventions can have convergent pathways and effects that are dependent on a matrix [11]. In this work, the correlation between the initial reaction and the markers that supported it was supportive to the environmentally responsive distribution of phenolic metabolites and seasonal variations in oxidative defense chemistry, but correlation is not sufficient to demonstrate mediation and the active constituent.

The clinical or biological significance of total flavonoid content and DPPH IC50 is also supported by previous studies with related endpoints [12]. The fact that their growth has occurred simultaneously enhances the hypothesis, but the confirmatory research in the future must specify whether the variables are secondary, mechanistic mediators or exploratory biomarkers.

The magnitude of the example effect needs to be viewed in the background of previous intervention research and evidence syntheses within the wider area [13]. The size was deliberatively realistic, and people or copies overlapped since pilot effects often tend to be smaller when tested in large independent samples.

The methodological evidence stresses the need of a standard measurement, the need of proper conditions of comparison, and the need to report in the complex interventions studies [14]. Bias can be reduced by replication, allocation concealment, blinded assessment, crossover control, or analytical calibration that is validated, but none can eliminate all the possible sources of error.

Tolerability, quality assurance, product stability, adherence, and interactions with habitual diet or medication are also critical to long-term translation. The literature on safety and implementation helps to consider all these factors along with efficacy instead of considering them after a positive primary outcome was achieved [15].

The research has a number of limitations. To begin with, the quantitative data is descriptive and cannot be used to make a scientific statement. Second, the presented sample and time frame might fail to detect rare negative occurrences or more long-term adjustment. Third, surrogate outcomes are not necessarily patient-important benefits. Fourth, response may be altered by unmeasured dietary, genetic, microbial, environmental, harvest or manufacturing factors.

Further research should include independent analytical confirmation, dose-ranging, preregistration, adequate power, and a predefined statistical analysis plan. Clinical studies should document ethics approval, trial registration, allocation procedures, adherence, and intention-to-treat analysis. Preclinical studies should report randomization, blinding, humane endpoints, exclusions, and batch-level chemical fingerprints.

From a translational perspective, identifying an optimal harvest window can improve batch consistency and pharmacognostic quality control. The intervention should be considered a potential adjunct or research lead rather than a replacement for established care. Replication, safety, cost, standardization, acceptability, and comparison with available alternatives should determine whether further development is justified.

Overall, the example findings support the study hypothesis and provide a coherent structure for a genuine investigation. Every numerical result, ethics statement, registration detail, disclosure, and analysis should be replaced or verified against the actual study record before scientific submission.

5. CONCLUSION

In this complete manuscript draft using dummy/example data, bark samples collected in four seasons produced a favorable change in total phenolic content compared with between-season comparison, with supporting changes in total flavonoid content, DPPH IC50, and FRAP value. The pattern was consistent with environmentally responsive allocation of phenolic metabolites and seasonal changes in oxidative defense chemistry and suggested potential relevance because identifying an optimal harvest window can improve batch consistency and pharmacognostic quality control. The draft is a systematic foundation of protocol development, data-collection planning, and subsequent preparation of the manuscript, but all numerical results should be substituted with ethically-generated and independently-confirmed data until the work can be presented as original research.

Declarations for Completion Before Submission

Ethics approval: Insert the actual institutional ethics committee name, approval number, approval date, and relevant consent or animal-welfare statement.

Trial registration: Insert the registry name and number for prospective clinical trials, where applicable.

Funding: Insert the verified funding source or state that no specific funding was received.

Conflicts of interest: Insert author-specific conflict-of-interest disclosures.

Data availability: Describe where the actual de-identified dataset and analysis code will be available.

Author contributions: Insert contribution statements using an accepted taxonomy such as CRediT.

REFERENCES

[1] Mandal S, Patra A, Samanta A, et al. Analysis of phytochemical profile of Terminalia arjuna bark extract with antioxidative and antimicrobial properties. Asian Pac J Trop Biomed. 2013;3(12):960-966. PMID:24093787.

[2] Amalraj A, Gopi S. Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: a review. J Tradit Complement Med. 2017;7(1):65-78. doi:10.1016/j.jtcme.2016.02.003. PMID:28053890.

[3] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53(10):4290-4302. doi:10.1021/jf0502698. PMID:15884874.

[4] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi:10.1021/acs.jnatprod.9b01285. PMID:32162523.

[5] Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582-1614. doi:10.1016/j.biotechadv.2015.08.001. PMID:26281720.

[6] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi:10.3389/fphar.2013.00177. PMID:24454289.

[7] Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183. doi:10.1016/j.redox.2015.01.002. PMID:25588755.

[8] Singh MK, Yadav SS, Gupta V, Khattri S. Immunomodulatory role of Emblica officinalis in arsenic-induced oxidative damage and apoptosis in thymocytes of mice. BMC Complement Altern Med. 2013;13:193. PMID:23889914.

[9] Sharma A, Sharma MK, Kumar M. Modulatory role of Emblica officinalis fruit extract against arsenic-induced oxidative stress in Swiss albino mice. Chem Biol Interact. 2009;180(1):20-30. PMID:19428342.

[10] Aggarwal A, Tandon S, Singla SK, Tandon C. Diminution of oxalate-induced renal tubular epithelial cell injury and inhibition of calcium oxalate crystallization by Tribulus terrestris. Int Braz J Urol. 2010;36(4):480-489. PMID:20815954.

[11] Mishra K, Dash AP, Dey N. Andrographolide: a novel antimalarial diterpene lactone compound from Andrographis paniculata and its interaction with curcumin and artesunate. J Trop Med. 2011;2011:579518. doi:10.1155/2011/579518. PMID:21760808.

[12] Muthusami S, Senthilkumar K, Vignesh C, et al. Effects of Cissus quadrangularis on proliferation, differentiation and matrix mineralization of human osteoblast-like SaOS-2 cells. J Cell Biochem. 2011;112(4):1035-1045. PMID:21308732.
[13] Parisuthiman D, Singhatanadgit W, Dechatiwongse T, Koontongkaew S. Cissus quadrangularis extract enhances biomineralization through up-regulation of MAPK-dependent alkaline phosphatase activity in osteoblasts. In Vitro Cell Dev Biol Anim. 2009;45(3-4):194-200. PMID:19057968.
[14] Ravi K, Divyashree P. Psidium guajava: a review on its potential as an adjunct in treating periodontal disease. Pharmacogn Rev. 2014;8(16):96-100. doi:10.4103/0973-7847.134233. PMCID:PMC4127827.
[15] Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20:225. doi:10.1186/s12906-020-02985-6. PMID:32680575.